The FDA's Pharmacy Compounding Advisory Committee has completed its two-day session.

Six of seven peptides were recommended for inclusion on the 503A Bulk Drug Substances List. One was voted down by a single vote.

Here are the final results — and what they actually mean for the road ahead. (For the Day 1 breakdown of the first four votes, see our July 23 coverage.)

The Final Vote Tally

| Compound | Vote (yes–no–abstain) | Recommendation | |---|---|---| | BPC-157 | 8–6–1 | ✅ Recommended for inclusion | | KPV | 8–6–1 | ✅ Recommended for inclusion | | TB-500 | 8–6–1 | ✅ Recommended for inclusion | | MOTS-c | 7–5–2 | ✅ Recommended for inclusion | | Semax | 8–5–1 | ✅ Recommended for inclusion | | Epitalon | 7–4 | ✅ Recommended for inclusion | | Emideltide (DSIP) | 6–7–1 | ❌ NOT recommended |

Six yes. One no — by a single vote.

Every recommendation in favor came over the FDA staff's own position. In its pre-meeting briefing documents, agency staff had proposed against adding these compounds to the list. The committee overrode that position on six of the seven.

What Each Vote Means

BPC-157, KPV, TB-500 — 8–6–1 (narrowest margin) The three compounds with the largest research communities and the most public-comment support all cleared with the same margin. Close votes on all three — reflecting a genuinely divided expert panel on compounds with extensive preclinical data but limited published human clinical-trial evidence.

MOTS-c — 7–5–2 The mitochondrial peptide cleared with a comparable margin and two abstentions. FDA reviewed MOTS-c for uses including obesity and osteoporosis.

Epitalon — 7–4 The bioregulator with the strongest longevity/anti-aging research base among the seven cleared on the second day. (Vote counts for the losing side were reported slightly differently across outlets; the recommendation itself is not in dispute.)

Semax — 8–5–1 The cognitive-focused peptide, delivered nasally rather than by injection, cleared with a moderate margin. It drew notably vocal support during the public-comment period.

Emideltide (DSIP) — 6–7–1 ❌ The only compound that did not make it — and the closest vote of the two days. DSIP (delta sleep-inducing peptide) was the meeting's surprise. According to the FDA briefing materials and reporting from the session, the panel's concern centered on a lack of safety and efficacy data to support its proposed uses (insomnia, narcolepsy, and opioid use disorder), inadequate characterization of the substance, and impurity risks tied to manufacturing. One committee member who moved to opposition cited concern about "potentially dangerous downstream consequences." One vote separated it from recommendation. The February 2027 PCAC meeting is a potential venue for reconsideration.

This Is Historic — With an Important Asterisk

Let's be honest about what happened this week.

An FDA advisory committee voted — six times — against the agency's own staff position. That is unusual. It reflects the political moment: a reconstituted committee, a current administration sympathetic to expanded peptide access, and a large volume of public comment on the docket making the case for regulated access over underground access.

That context matters for understanding how this happened.

It does not change what happens next — which is a process the FDA controls.

What Happens Next — The Actual Path to Legal Access

A positive PCAC recommendation is necessary but not sufficient for legal compounding access. Here is the precise sequence:

Step 1 — Completed: PCAC votes (July 23-24, 2026) ✅

Step 2: FDA reviews committee recommendations alongside all public comments filed to docket FDA-2025-N-6895 and the full scientific record

Step 3: FDA publishes a proposed rule to add recommended substances to the 503A Bulks List — this opens a new public comment period

Step 4: FDA reviews public comments on the proposed rule

Step 5: FDA publishes a final rule

Step 6: Only after the final rule takes effect can licensed 503A compounding pharmacies legally compound these substances under physician prescription

Realistic timeline: Regulatory analysts covering the meeting estimate a formal rulemaking cycle that realistically runs many months — late 2026 at the absolute earliest, with 2027 the more realistic target for final determinations.

The FDA is not legally required to follow the committee's recommendation. It usually does — but it is not obligated to.

What This Does NOT Mean

The next few days will produce a lot of inaccurate takes. Here is the precise list of things that did not happen this week:

BPC-157 is not FDA approved. It was recommended for the compounding list — not approved as a drug.

Compounding pharmacies cannot start making these today. The 503A Bulks List has not been updated. The same legal framework from yesterday applies today.

Access has not changed. Nothing is more or less legal today than it was on July 22. The recommendation is the input to a process, not the end of it.

This is not legalization. Even after final rulemaking, these would be available through licensed compounding pharmacies under physician prescription — a specific, supervised clinical pathway. Not over-the-counter. Not unregulated.

What This DOES Mean

The formal pathway toward legal compounded access is now open for six of the seven compounds. For the first time, a positive committee recommendation exists on the record for BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. That is what the rulemaking process requires to move forward.

The public comment produced results. Physicians, patients, researchers, and compounding-pharmacy representatives filed comments and testified publicly. The committee heard it and voted accordingly on six of the seven.

The legitimate-access argument won the committee room. The core argument — that people are already accessing these compounds, that driving them further underground doesn't eliminate risk but eliminates oversight, and that a regulated compounding pathway is safer than the status quo — persuaded the majority on six compounds.

DSIP (Emideltide) remains in regulatory limbo. One vote away from recommendation. The February 2027 PCAC meeting reviewing additional peptides is a potential future venue for reconsideration.

For People on Protocols Right Now

Nothing changes today. Your current access situation — whatever it is — is unchanged by the committee vote.

The trajectory is favorable for six compounds. If the FDA follows the committee recommendation and completes rulemaking, licensed compounding access under physician prescription becomes available. That's a meaningful change in the access landscape — but it takes time.

Track your protocol regardless of what the FDA does. Whether access expands or contracts, having a clear record of what you've been running, what it's done to your body composition and biomarkers, and what your baseline looks like is essential. If access changes — in either direction — your data is what you and your doctor use to make informed decisions.

The Bottom Line

This was the strongest realistic outcome from the PCAC meeting — 6 of 7 compounds recommended, every one of them over the FDA staff position. DSIP narrowly missed by a single vote.

It is not legalization. It is not FDA approval. It is not immediate access.

It is the most significant regulatory progress in the peptide compounding space in years — and the beginning of a formal rulemaking process that will determine whether that progress becomes law.

We'll continue covering every step as it unfolds.

→ Follow the latest at PeptidesGPT.com/research

Sources:

Regulatory Affairs Professionals Society (RAPS): "FDA advisory committee backs two more peptides, rejects one for compounding list" — raps.org (July 24, 2026)
STAT News: "FDA advisory panel narrowly rejects compounding of one peptide, backs two others" — statnews.com (July 24, 2026)
Bloomberg Law: "FDA Advisers Back Looser Rules For Six Peptides, Reject One" — news.bloomberglaw.com (July 24, 2026)
FiercePharma: "Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback" — fiercepharma.com (July 24, 2026)
NPR: "FDA advisers vote to ease peptide restrictions, despite agency concerns" — npr.org (July 23, 2026)
Medical Daily: "FDA Advisory Panel Votes to Loosen Rules on BPC-157, TB-500, and MOTS-C Despite Agency Scientists' Opposition" — medicaldaily.com (July 23, 2026)
Orrick, Herrington & Sutcliffe: "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting" — orrick.com (July 2026)
U.S. FDA: "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee" (docket FDA-2025-N-6895) — fda.gov

PeptidesGPT is an educational platform. The content above is for informational purposes only and does not constitute medical advice or legal advice. Always consult a licensed healthcare provider before making decisions about your health or protocol.